4.7 Article

The origin of bladder cancer from mucosal field effects

期刊

ISCIENCE
卷 25, 期 7, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.isci.2022.104551

关键词

-

资金

  1. NCI Genitourinary Bladder SPORE Grant [P50CA 91846]
  2. Cancer Prevention and Research Institute of Texas (CPRIT) [RP220021]
  3. MDACC Nathan W. Lassiter Endowment
  4. Donor Funds
  5. Polish National Science Centre [2018/29/B/ST7/02550, 2016/23/D/ST7/03665]
  6. European Union Fund [POWR.03.02.00-00-I029]
  7. National Institute of Health [R01HL136333, R01HL134880]

向作者/读者索取更多资源

Whole-organ mapping identified dysregulated pathways and immune response involvement in bladder cancer development. Aberrant methylation/expression of genes and different types of mutations were found to be associated with disease progression. The carcinogenesis process can be divided into dormant and progressive phases.
Whole-organ mapping was used to study molecular changes in the evolution of bladder cancer from field effects. We identified more than 100 dysreglated pathways, involving immunity, differentiation, and transformation, as initiators of carcinogenesis. Dysregulation of interleukins signified the involvement of inflammation in the incipient phases of the process. An aberrant methylation/expression of multiple HOX genes signified dysregulation of the differentiation program. We identified three types of mutations based on their geographic distribution. The most common were mutations restricted to individual mucosal samples that targeted uroprogenitor cells. Two types of mutations were associated with clonal expansion and involved large areas of mucosa. The alpha mutations occurred at low frequencies while the beta mutations increased in frequency with disease progression. Modeling revealed that bladder carcinogenesis spans 10-15 years and can be divided into dormant and progressive phases. The progressive phase lasted 1-2 years and was driven by beta mutations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据